Reveal Genomics plans to have assays available within three years, and is eager to partner with pharmaceutical and diagnostics companies to fulfill its vision.
In Nature this week: molecular profiling platform identifies treatments for pediatric cancer cases, metaFlye algorithm addresses challenges of long-read metagenomic assembly, and more.
A Lund University-led team developed two methylation risk scores to predict which patients would or would not respond to treatment and experience side effects.
The findings suggested that genomic surveillance of Barrett's esophagus could identify patients who will progress years in advance and enable earlier treatment.
